EIR Biopharma is hoping to bring in $17.1 million from an IPO on the New York Stock Exchange that could fund developm...
EIR Biopharma filed for a New York Stock Exchange IPO to raise $17.1 million to fund development of a preclinical eye-disease drug.
Why it mattersThe $17.1 million NYSE IPO raise for a preclinical eye-disease program requires investors to reassess clinical funding timelines.